TGFb inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “TGF-Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in TGF-Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TGF-Beta Inhibitors: Overview
Transforming growth factor (TGF)-? is a secreted multifunctional cytokine that signals via plasma membrane TGF-? type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF-? signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF-? can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF-? in cancer cells are blocked, TGF-? signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses.
Transforming growth factor ? (TGF-?) is part of a larger superfamily of secreted dimeric multifunctional proteins that also includes activins and bone morphogenetic proteins. It plays an important role in embryogenesis and in maintaining tissue homeostasis in multicellular organisms. TGF-? elicits highly context-dependent effects on many different cell types. Hence, anomalous TGF-? signaling can result in numerous diseases, including cancer. TGF-? signaling can have a dual role in cancer
Report Highlights
This segment of the TGF-Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TGF-Beta Inhibitors Emerging Drugs
Further product details are provided in the report……..
TGF-Beta Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TGF-Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
TGF-Beta Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGF-Beta Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGF-Beta Inhibitors drugs.
TGF-Beta Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TGF-Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in TGF-Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TGF-Beta Inhibitors: Overview
Transforming growth factor (TGF)-? is a secreted multifunctional cytokine that signals via plasma membrane TGF-? type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF-? signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF-? can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF-? in cancer cells are blocked, TGF-? signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses.
Transforming growth factor ? (TGF-?) is part of a larger superfamily of secreted dimeric multifunctional proteins that also includes activins and bone morphogenetic proteins. It plays an important role in embryogenesis and in maintaining tissue homeostasis in multicellular organisms. TGF-? elicits highly context-dependent effects on many different cell types. Hence, anomalous TGF-? signaling can result in numerous diseases, including cancer. TGF-? signaling can have a dual role in cancer
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TGF-Beta Inhibitors R&D. The therapies under development are focused on novel approaches for TGF-Beta Inhibitors.
- In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio.
This segment of the TGF-Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TGF-Beta Inhibitors Emerging Drugs
- Luspatercept - Acceleron Pharma
Further product details are provided in the report……..
TGF-Beta Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TGF-Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TGF-Beta Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TGF-Beta Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGF-Beta Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGF-Beta Inhibitors drugs.
TGF-Beta Inhibitors Report Insights
- TGF-Beta Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TGF-Beta Inhibitors drugs?
- How many TGF-Beta Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for TGF-Beta Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TGF-Beta Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TGF-Beta Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Acceleron Pharma
- Isarna Therapeutics
- Forbius
- Luspatercept
- ISTH0036
- ISTH1106
- ISTH0047
- ISTH1047
- AVID 200
Introduction
Executive Summary
TGF-Beta Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TGF-Beta Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TGF-Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TGF-Beta Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Luspatercept - Acceleron Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ISTH0036: Isarna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ISTH1106: Isarna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TGF-Beta Inhibitors Key Companies
TGF-Beta Inhibitors Key Products
TGF-Beta Inhibitors- Unmet Needs
TGF-Beta Inhibitors- Market Drivers and Barriers
TGF-Beta Inhibitors- Future Perspectives and Conclusion
TGF-Beta Inhibitors Analyst Views
TGF-Beta Inhibitors Key Companies
Executive Summary
TGF-Beta Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TGF-Beta Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TGF-Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TGF-Beta Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Luspatercept - Acceleron Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ISTH0036: Isarna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ISTH1106: Isarna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TGF-Beta Inhibitors Key Companies
TGF-Beta Inhibitors Key Products
TGF-Beta Inhibitors- Unmet Needs
TGF-Beta Inhibitors- Market Drivers and Barriers
TGF-Beta Inhibitors- Future Perspectives and Conclusion
TGF-Beta Inhibitors Analyst Views
TGF-Beta Inhibitors Key Companies
LIST OF TABLES
Table 1 Total Products for TGF-Beta Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for TGF-Beta Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for TGF-Beta Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for TGF-Beta Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
